Visit the Children with Cancer UK website CHILDREN with CANCER UK


These are the excellent presentations from the Children with Cancer UK sponsored childhood cancer session organised by Professor Denis Henshaw for the 8th Princess Chulabhorn International Scientific Congress held in Thailand in November 2016.

Precision Medicine in Childhood and TYA Cancer Hype or Hope?

The Trustees of CwC UK are keen to make a major contribution this technology in the UK by funding research and professional meetings. This meeting is primarily about higher precision diagnosis and treatment; our 2018 meeting next year will focus on causal factors. Progress in molecular and cellular biotechnologies has heralded the advent of an era of precision cancer medicine in which real time use of molecular genetics, proteomics and phenomics can be used for better diagnosis and hence deliver more effective, less toxic therapies. This meeting is intended to help professionals better understand the progress and ongoing challenges in this field and how we might meet them to ensure that precision diagnosis and, where available, targeted therapy is available to all children and young adults in the UK at diagnosis.

Day 1 - Monday 18th September 2017

1030 Session 1     Introduction and Progress Update

1030 Welcome and Introduction     CwC UK and Conference Chair
         Dr Nick Goulden, Medical Director of Children with Cancer UK
         Dr Olaf Heidenreich, Professor of Molecular Haematology, Wolfson Childhood Cancer Research Centre

1045 Update on Immunotherapy     Professor Persis Amrolia
         Professor of Transplantation Immunology, UCL Institute of Child Health and
         Consultant in Bone Marrow Transplant, Great Ormond Street Hospital for Children

1115 Brain Tumour Initiative     Professor David Walker
         Professor of Paediatric Oncology, Children’s Brain Tumour Research Centre, University of Nottingham and
         Honorary Consultant in Paediatric Oncology, Nottingham Children’s Hospital

1145 Causation /Prevention     Dr Mark Miller
         Assistant Clinical Professor, University of California San Francisco (UCSF), and
         School of Medicine, Departments of Pediatrics and Internal Medicine, and
         Co-Director of the UCSF Pediatric Environmental Health Specialty Unit (PEHSU), and
         Director, Children’s Environmental Health Program, California Environmental Protection Agency

1215 Future initiatives         CwC UK speaker to be confirmed
         Update on CwC UK's thinking on our priorities for research grant funding in the next few years

1230-1330 Lunch

1330 Session 2     Improving accuracy of diagnosis and risk stratification
Sub-classification of diseases in order to refine diagnosis, more accurately stratify prognosis and guide therapy has been a feature of paediatric oncology for over 50 years. New technologies have strengthened this effort, in some cases re-defining disease types and also allowing a more accurate diagnosis, with implications for therapy and causation. In addition the enhanced sensitivity provided by modern sequencing technologies means that liquid biopsy of circulating DNA rather than biopsy of bulk tumour is now a reality. These developments will be illustrated by four plenary presentations, covering medulloblastoma, acute myeloid leukaemia, rare haematological malignancies and rare solid tumours.

1330 Medulloblastoma     Professor Steve Clifford
         Professor of Molecular Paediatric Oncology, Northern Institute for Cancer Research, Newcastle University

1400 Acute Myeloid Leukaemia     Dr Phil Ancliff
         Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children

1430 Rare Hematologic Malignancies     Dr Anupama Rao
         Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children

1500 Rare solid tumours     Dr Tom Jacques
         Reader in Paediatric Neuropathology, UCL Institute of Child Health and
         Histopathology Laboratory, Great Ormond Street Hospital for Children

1530-1600 Refreshments and comfort break

1600 Session 3     Integrating Genomics and Disease Modelling to Develop Targeted Therapies
Pre-clinical science holds the key to successfully harnessing the potential power of precision treatment. In this session three leading experts will illustrate approaches to discovery of new targets in acute leukaemia, brain tumours and neuroblastoma. They will focus on the importance of the development of preclinical models that replicate the changes seen in specific tumours as well as the need to study both diagnostic and relapse material. Each speaker will also show how an understanding the role of germline changes is beginning to allow us to understand the molecular steps involved in the development of cancer

1600 Acute Leukaemia     Professor Olaf Heidenreich Newcastle
         Professor of Molecular Haematology, Wolfson Childhood Cancer Research Centre
         Senior Lecturer for Paediatric Molecular Oncology and Childhood Cancer Theme Lead
         Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University Medical School

1630 Brain tumours     Professor Amar Gajjar
         Chair of Pediatric Medicine, St Jude Children's Research Hospital, Mephis, USA
         Co-Chair, Department of Oncology, St Jude Children's Research Hospital, Mephis, USA
         Director, Neuro-Oncology Division and Brain Tumor Program, St Jude Children's Research Hospital.

1700 Solid Tumours/Neuroblastoma     Professor Lou Chesler
         Team Leader Paediatric Solid Tumour Biology and Therapeutics, Institute of Cancer Research, London
         Honorary Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London

1730 Session 4     Poster Session with Refreshments with Presentation of Prizes at 1830
A call for Poster Abstracts of original research, for presentation at the meeting focusing, on the use of precision medicine in diagnostics and targeted therapy has been issued. The conference scientific committee will select up to three leading abstracts for oral presentation. Posters for all accepted abstracts will be display in this session which will be followed by the conference dinner

1900 Children with Cancer UK Conference Dinner
The Conference Dinner is an integral part of this conference and is included in the price. It is at the same venue and will provide a good opportunity for networking with other researchers and clinicians.


Day 2 - Tuesday 19th September 2017

0845 Session 5     Current & Future Clinical Trials of Targeted Therapy
Proof of the value of precision medicine can only come from well-designed clinical trials. In this session four experts will discuss the challenges of moving from the preclinical to clinical application, the role of pharmacology and the challenges in designing trials of medicines targeted at genomic changes that may often occur at low frequency and in multiple tumour types. The final speaker in this session will discuss the health economics and the need to balance funding constraints with a commitment to improve survival and quality of survival.

0845 Preclinics to Early Phase     Professor Birgit Geoerger
         Head of Paediatric Clinical Research, Institut Gustave Roussy, Paris, France

0910 Pharmacology     Dr Gareth Veal
         Senior Lecturer in Pharmacology, Northern Institute for Cancer Research, Newcastle University

0935 Clinical Trial Design     speaker to be confirmed

1000 Health economics of targeted therapy     speaker to be confirmed

1030-1100 Refreshments and comfort break

1100 Session 6     Oral presentation of best 3 Abstracts - introduced by a senior sponsor
A call for Poster Abstracts of original research focusing on the use of precision medicine in diagnostics and targeted therapy has been be issued by CwC UK. The conference scientific committee will select up to three leading Poster Abstracts for oral presentation.

1200 Session 7     Presentation of UK Initiatives in Precision Medicine
This final session of the main meeting will discuss two important precision medicine initiatives funded in significant part by CwC UK – namely the SMPaeds and INSTINCT projects. Speakers will outline the aims and scope of these projects and how they can be accessed by individual clinical centres

1200 SMPaeds & Instinct Projects    Professor Lou Chesler and another speaker TBC
         Team Leader Paediatric Solid Tumour Biology and Therapeutics, Institute of Cancer Research, London
         Honorary Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London

1300-1400 Lunch

1400 Session 8     Workshop Integrating genomics into studies of toxicity and quality of survival

1400-1600 Workshop led by:
         Dr Rod Skinner, Consultant in Paediatric Oncology/Bone Marrow Transplantation, Newcastle NHS Hospitals Trust
         Dr Sujith Samarasinghe, Consultant Paediatric Haematologist, Great Ormond Street Hospital, London

Much of the focus of the value of precision medicine has been on the development of new targeted therapies. Nevertheless, it is important to recognise that many children and young adults will continue to receive standard therapy with its attendant short and long term side effects. This workshop aims to understand how the use of genetic technologies to predict both short and long term toxicities might be incorporated into clinical trials.

1600 Conference ends

This page was last updated 19th April 2017 at 09:47

© 2017 CHILDREN with CANCER UK
51 Great Ormond Street, London, WC1N 3JQ
Tel: 020 7404 0808,     Registered Charity Number: 298405
Inaugurated by Diana, Princess of Wales